X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (27) 27
humans (25) 25
male (23) 23
middle aged (21) 21
female (20) 20
adult (18) 18
aged (18) 18
oncology (15) 15
cancer (13) 13
care and treatment (12) 12
chemotherapy (11) 11
lung neoplasms - drug therapy (11) 11
lung cancer (9) 9
lung cancer, non-small cell (9) 9
lung neoplasms - pathology (9) 9
neoplasm staging (9) 9
carcinoma, non-small-cell lung - drug therapy (8) 8
clinical trials (8) 8
survival (8) 8
hematology, oncology and palliative medicine (7) 7
aged, 80 and over (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
cancer therapies (6) 6
carcinoma, non-small-cell lung - pathology (6) 6
lung neoplasms - genetics (6) 6
mutation (6) 6
prognosis (6) 6
respiratory system (6) 6
risk factors (6) 6
surgery (6) 6
carcinoma, non-small-cell lung - genetics (5) 5
disease-free survival (5) 5
medical colleges (5) 5
patients (5) 5
research (5) 5
treatment outcome (5) 5
analysis (4) 4
anaplastic lymphoma kinase (4) 4
cell lung-cancer (4) 4
cisplatin (4) 4
cisplatin - administration & dosage (4) 4
japan (4) 4
japanese (4) 4
kaplan-meier estimate (4) 4
lung neoplasms - mortality (4) 4
medical research (4) 4
medicine & public health (4) 4
metastasis (4) 4
neutropenia (4) 4
non-small cell lung cancer (4) 4
original (4) 4
original article (4) 4
product development (4) 4
receptor protein-tyrosine kinases - genetics (4) 4
toxicity (4) 4
trial (4) 4
tumors (4) 4
abridged index medicus (3) 3
animals (3) 3
article (3) 3
asian continental ancestry group (3) 3
astronomy & astrophysics (3) 3
c-reactive protein (3) 3
carcinoma, non-small-cell lung - mortality (3) 3
carcinoma, squamous cell - drug therapy (3) 3
college teachers (3) 3
combination (3) 3
cross-sectional studies (3) 3
diarrhea (3) 3
drug dosages (3) 3
efficacy (3) 3
gene rearrangement (3) 3
health aspects (3) 3
iii trial (3) 3
internal medicine (3) 3
kinases (3) 3
maximum tolerated dose (3) 3
medical prognosis (3) 3
oncology, experimental (3) 3
pharmaceutical industry (3) 3
physics, multidisciplinary (3) 3
physics, particles & fields (3) 3
physiological aspects (3) 3
protein kinase inhibitors - therapeutic use (3) 3
pulmonary/respiratory (3) 3
pyrazoles - therapeutic use (3) 3
pyridines - therapeutic use (3) 3
quinazolines - administration & dosage (3) 3
receptor protein-tyrosine kinases - antagonists & inhibitors (3) 3
receptor, epidermal growth factor - genetics (3) 3
respiratory agents (3) 3
retrospective studies (3) 3
safety (3) 3
survival rate (3) 3
therapy (3) 3
adenocarcinoma (2) 2
adenocarcinoma - drug therapy (2) 2
adenocarcinoma - genetics (2) 2
albumin (2) 2
alk inhibitors (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 2, pp. 121 - 128
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer... 
Hematology, Oncology and Palliative Medicine | TRIAL | GROWTH-FACTOR RECEPTOR | CISPLATIN PLUS GEMCITABINE | GEFITINIB | PLACEBO | EFFICACY | NSCLC | ONCOLOGY | DOUBLE-BLIND | COMBINATION | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 663 - 671
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2017, Volume 5, Issue 1, pp. 42 - 50
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1630 - 1638
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1147 - 1157
Journal Article
Respiratory Investigation, ISSN 2212-5345, 2014, Volume 52, Issue 6, pp. 330 - 338
Journal Article
Annals of Thoracic Surgery, ISSN 0003-4975, 2013, Volume 96, Issue 5, pp. 1783 - 1789
Journal Article